NO793759L - Vandig blanding. - Google Patents
Vandig blanding.Info
- Publication number
- NO793759L NO793759L NO793759A NO793759A NO793759L NO 793759 L NO793759 L NO 793759L NO 793759 A NO793759 A NO 793759A NO 793759 A NO793759 A NO 793759A NO 793759 L NO793759 L NO 793759L
- Authority
- NO
- Norway
- Prior art keywords
- lecithin
- water
- dihexanoyl
- pharmaceutical active
- approx
- Prior art date
Links
- 238000002156 mixing Methods 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 claims description 34
- DVZARZBAWHITHR-GOSISDBHSA-N 1,2-dihexanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCC(=O)OC[C@@H](OC(=O)CCCCC)COP([O-])(=O)OCC[N+](C)(C)C DVZARZBAWHITHR-GOSISDBHSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 9
- 239000008347 soybean phospholipid Substances 0.000 claims description 9
- 229960003529 diazepam Drugs 0.000 claims description 8
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 6
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- 230000002949 hemolytic effect Effects 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 claims description 2
- QIJYAMAPPUXBSC-CQSZACIVSA-N PC(4:0/4:0) Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)COP([O-])(=O)OCC[N+](C)(C)C QIJYAMAPPUXBSC-CQSZACIVSA-N 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- CITHEXJVPOWHKC-UHFFFAOYSA-N dimyristoyl phosphatidylcholine Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UHFFFAOYSA-N 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000008055 phosphate buffer solution Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000693 micelle Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1192178 | 1978-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO793759L true NO793759L (no) | 1980-05-22 |
Family
ID=4378189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO793759A NO793759L (no) | 1978-11-21 | 1979-11-20 | Vandig blanding. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4271196A (id) |
| EP (1) | EP0011745B1 (id) |
| JP (1) | JPS5572111A (id) |
| KR (1) | KR850000584B1 (id) |
| AR (1) | AR225294A1 (id) |
| AT (1) | ATE501T1 (id) |
| AU (1) | AU529061B2 (id) |
| CA (1) | CA1136988A (id) |
| DE (1) | DE2961718D1 (id) |
| DK (1) | DK494079A (id) |
| ES (1) | ES8101855A1 (id) |
| FI (1) | FI793461A (id) |
| GR (1) | GR73668B (id) |
| HU (1) | HU180792B (id) |
| IE (1) | IE48659B1 (id) |
| IL (1) | IL58723A (id) |
| MC (1) | MC1297A1 (id) |
| NO (1) | NO793759L (id) |
| NZ (1) | NZ192118A (id) |
| PH (1) | PH15561A (id) |
| PT (1) | PT70478A (id) |
| ZA (1) | ZA796116B (id) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2952115C2 (de) * | 1979-12-22 | 1982-05-06 | A. Nattermann & Cie GmbH, 5000 Köln | Rosmarinsäure-Phospholipid-Komplex |
| US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
| US4457918A (en) * | 1982-05-12 | 1984-07-03 | The General Hospital Corporation | Glycosides of vitamins A, E and K |
| CA1237670A (en) * | 1983-05-26 | 1988-06-07 | Andrew S. Janoff | Drug preparations of reduced toxicity |
| US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
| US4622219A (en) * | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| US4891208A (en) * | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
| PT78628B (en) * | 1984-05-02 | 1986-06-18 | Liposome Co Inc | Pharmaceutical composition with reduced toxicity |
| US5023271A (en) * | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| US5041278A (en) * | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
| IT1269569B (it) * | 1994-04-22 | 1997-04-08 | Ugo Citernesi | Procedimento per la preparazione di complessi fra fosfolipidi e principi attivi utili per la produzione di liposomi e principi attivi e liposomi ottenuti con il procedimento |
| EP0682943B1 (de) * | 1994-05-20 | 2003-08-20 | GESELLSCHAFT FÜR MEDIZINISCHE FORSCHUNG UND WEITERBILDUNG e.V. GMF | Lormetazepamhaltige Öl-in-Wasser-Emulsion |
| JP2740153B2 (ja) * | 1995-03-07 | 1998-04-15 | エフ・ホフマン−ラ ロシユ アーゲー | 混合ミセル |
| US6576264B1 (en) | 1995-10-17 | 2003-06-10 | Skyepharma Canada Inc. | Insoluble drug delivery |
| US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| ES2201673T3 (es) * | 1998-02-11 | 2004-03-16 | Rtp Pharma Corporation | Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios. |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| JP2002516267A (ja) | 1998-05-29 | 2002-06-04 | アールティーピー・ファーマ・インコーポレーテッド | 熱的に保護された微粒子組成物及びその最終蒸気滅菌 |
| WO2000010531A1 (en) | 1998-08-19 | 2000-03-02 | Rtp Pharma Inc. | Injectable aqueous dispersions of propofol |
| PL201578B1 (pl) | 1998-11-20 | 2009-04-30 | Skyepharma Canada Inc | Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku |
| US6447806B1 (en) | 1999-02-25 | 2002-09-10 | Novartis Ag | Pharmaceutical compositions comprised of stabilized peptide particles |
| AU7984200A (en) * | 1999-09-21 | 2001-04-24 | Skyepharma Canada Inc. | Surface modified particulate compositions of biologically active substances |
| AU2001257115B2 (en) | 2000-04-20 | 2005-01-27 | Rtp Pharma Inc. | Improved water-insoluble drug particle process |
| CA2420597C (en) | 2000-08-31 | 2011-05-17 | Rtp Pharma Inc. | Milled particles |
| US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
| TWI354568B (en) * | 2000-09-20 | 2011-12-21 | Jagotec Ag | Insoluble drug particle compositions with improved |
| US6534088B2 (en) * | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
| FR2833842B1 (fr) * | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU29060A1 (id) * | ||||
| LU28584A1 (id) * | ||||
| FR2102537A5 (id) * | 1970-08-07 | 1972-04-07 | Ugine Kuhlmann | |
| FR2270887A1 (en) * | 1974-05-16 | 1975-12-12 | Chabrier De Lassauniere Pierre | Prepn of lecithins and glycol-lecithins - by reaction of trimethylamine with 2-substd-2-oxo-1,3,2-dioxaphospholans |
| SE442014B (sv) * | 1976-10-12 | 1985-11-25 | Barry D Sears | Syntetisk fosfatidyl-kvarter ammoniumforening till anvendning for solubilisering eller emulgering av vattenolosliga foreningar |
-
1979
- 1979-01-24 GR GR60545A patent/GR73668B/el unknown
- 1979-10-03 CA CA000336919A patent/CA1136988A/en not_active Expired
- 1979-10-24 AR AR278611A patent/AR225294A1/es active
- 1979-11-05 FI FI793461A patent/FI793461A/fi not_active Application Discontinuation
- 1979-11-08 AT AT79104378T patent/ATE501T1/de not_active IP Right Cessation
- 1979-11-08 DE DE7979104378T patent/DE2961718D1/de not_active Expired
- 1979-11-08 EP EP79104378A patent/EP0011745B1/de not_active Expired
- 1979-11-12 PH PH23274A patent/PH15561A/en unknown
- 1979-11-14 AU AU52824/79A patent/AU529061B2/en not_active Ceased
- 1979-11-14 IL IL58723A patent/IL58723A/xx unknown
- 1979-11-14 ZA ZA00796116A patent/ZA796116B/xx unknown
- 1979-11-14 NZ NZ192118A patent/NZ192118A/xx unknown
- 1979-11-15 MC MC791415A patent/MC1297A1/xx unknown
- 1979-11-16 HU HU79HO2196A patent/HU180792B/hu unknown
- 1979-11-16 US US06/094,813 patent/US4271196A/en not_active Expired - Lifetime
- 1979-11-19 JP JP14903879A patent/JPS5572111A/ja active Granted
- 1979-11-20 NO NO793759A patent/NO793759L/no unknown
- 1979-11-20 DK DK494079A patent/DK494079A/da not_active Application Discontinuation
- 1979-11-20 KR KR7904064A patent/KR850000584B1/ko active
- 1979-11-20 IE IE2216/79A patent/IE48659B1/en unknown
- 1979-11-20 PT PT70478A patent/PT70478A/pt unknown
- 1979-11-20 ES ES486157A patent/ES8101855A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI793461A (fi) | 1980-05-22 |
| EP0011745A1 (de) | 1980-06-11 |
| ZA796116B (en) | 1980-11-26 |
| DE2961718D1 (en) | 1982-02-18 |
| IL58723A0 (en) | 1980-02-29 |
| NZ192118A (en) | 1981-12-15 |
| DK494079A (da) | 1980-05-22 |
| HU180792B (en) | 1983-04-29 |
| IE48659B1 (en) | 1985-04-03 |
| JPH0122243B2 (id) | 1989-04-25 |
| JPS5572111A (en) | 1980-05-30 |
| CA1136988A (en) | 1982-12-07 |
| GR73668B (id) | 1984-03-28 |
| EP0011745B1 (de) | 1981-12-30 |
| PH15561A (en) | 1983-02-11 |
| ATE501T1 (de) | 1982-01-15 |
| ES486157A0 (es) | 1981-01-16 |
| PT70478A (en) | 1979-12-01 |
| MC1297A1 (fr) | 1980-10-03 |
| IE792216L (en) | 1980-05-21 |
| US4271196A (en) | 1981-06-02 |
| AR225294A1 (es) | 1982-03-15 |
| IL58723A (en) | 1982-11-30 |
| ES8101855A1 (es) | 1981-01-16 |
| KR850000584B1 (ko) | 1985-04-30 |
| AU5282479A (en) | 1980-05-29 |
| AU529061B2 (en) | 1983-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO793759L (no) | Vandig blanding. | |
| US4158707A (en) | Parenteral preparations | |
| DK175662B1 (da) | Blandingsmicelleoplösninger med ikke-steroide inflammationshæmmmere | |
| US6605298B1 (en) | Pharmaceutical compositions and their use | |
| EP1389089B1 (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
| US4328222A (en) | Pharmaceutical compositions for parenteral or local administration | |
| CN103110579B (zh) | 前列地尔注射剂 | |
| DK165219B (da) | Medikamentholdigt lipidvesikelpraeparat og fremgangsmaade til fremstilling deraf | |
| KR101391020B1 (ko) | 수난용성 약제를 함유한 약학 조성물 | |
| JP2000319170A (ja) | テプレノン含有点眼剤 | |
| JPH047722B2 (id) | ||
| FI94835B (fi) | Menetelmä 2-fenyyli-1,2-bentsisoselenatsol-3(2H)-onin stabiilien parenteraalisten liuosten valmistamiseksi | |
| US20140329774A1 (en) | Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof | |
| CN101632634B (zh) | N(2)-l-丙氨酰-l-谷氨酰胺脂质体注射剂及其制备方法 | |
| NO873626L (no) | Fremgangsmaate for fremstilling av frysetoerkede farmasoeytiske preparater av fenylkinolinkarboksylsyrer. | |
| JPH06239734A (ja) | リポソームの調製法及びリポソーム製剤 | |
| JPH04505018A (ja) | 水性混合ミセル溶液を製造する方法 | |
| EP0409936B1 (de) | Verfahren zur herstellung wässriger mischmicellösungen | |
| JPWO2002053154A1 (ja) | エマルション製剤 | |
| NO150183B (no) | Fremgangsmaate ved fremstilling av injeksjonsloesninger | |
| JPH02289511A (ja) | 混合ミセル | |
| CN101904817A (zh) | 一种头孢磺啶钠脂质体注射剂 | |
| JPH06256212A (ja) | オーレオバシジン類のリポソーム製剤 | |
| CN107519187A (zh) | 一种脂溶性维生素冻干乳的制备方法 | |
| DK146754B (da) | Fremgangsmaade til fremstilling af vandige oploesninger af sterolglykosider eller esterderivater deraf |